| |
Infectious SIRS (n = 47)
|
Non-infectious SIRS (n = 95)
|
p value
|
|---|
|
Age (year)
|
67.8 ± 15.7
|
67.2 ± 13.3
|
0.81
|
|
Gender, n (%)
| | |
0.77
|
|
Male
|
32 (68.1)
|
67 (70.5)
| |
|
Female
|
15 (31.9)
|
28 (29.5)
| |
|
Type of surgery, n (%)
| | | |
|
Valve surgery
|
16 (34.0)
|
36 (37.9)
|
0.65
|
|
CABG
|
9 (19.1)
|
11 (11.6)
|
0.22
|
|
Vessel replacement
|
13 (27.7)
|
21 (22.7)
|
0.47
|
|
VAD
|
3 (6.4)
|
1 (1.1)
|
0.11
|
|
Interventional therapy
|
1 (2.1)
|
14 (14.7)
|
0.02
|
|
Complex surgery
|
5 (10.6)
|
12 (12.6)
|
0.73
|
|
BMI, kg/m2
|
21.8 (20.0,26.7)
|
22.7 (20.4,24.7)
|
0.64
|
|
Concomitant disease, n (%)
| | | |
|
Diabetes mellitus
|
18 (38.3)
|
25 (26.3)
|
0.14
|
|
Hypertension
|
20 (42.6)
|
35 (36.8)
|
0.51
|
|
CKD
|
19 (40.4)
|
21 (22.1)
|
0.02
|
|
CPB duration, min
|
197.2 ± 142.5
|
173.6 ± 123.5
|
0.31
|
|
Aortic cross clamping, min
|
99.0 ± 100.1
|
98.3 ± 84.7
|
0.96
|
|
Operation time, min
|
508.9 ± 192.4
|
466.3 ± 174.9
|
0.19
|
|
Blood loss, mL
|
3,512 ± 3,150
|
3,189 ± 2,706
|
0.53
|
|
APACHE II
|
19.0 (15.0,25.0)
|
11.0 (9.0,14.0)
|
0.001
|
|
SOFA
|
7.0 ± 2.6
|
5.1 ± 2.1
|
0.001
|
|
PCT, ng/mL
|
2.80 (1.24,10.20)
|
0.10 (0.06,0.21)
|
0.001
|
|
WBC, ×103/μL
|
15.5 (11.0,22.6)
|
9.3 (7.2,12.6)
|
0.001
|
|
CRP, mg/dL
|
15.8 (12.0,19.9)
|
5.8 (2.5,8.9)
|
0.001
|
|
ICU stay, day
|
23.0 (12.0,52.0)
|
5.0 (3.0,6.0)
|
0.001
|
|
Hospital stay, day
|
82.0 (37.0,149.0)
|
31.0 (23.0,45.0)
|
0.001
|
|
MV duration, h
|
264.0 (40.0,999.0)
|
17.0 (10.0,39.0)
|
0.001
|
|
CRRT, n (%)
|
26 (55.3)
|
5 (5.3)
|
0.001
|
|
PMX-DHP, n (%)
|
18 (38.3)
|
0
|
0.001
|
|
ECMO, n (%)
|
13 (27.7)
|
0
|
0.001
|
|
DIC, n (%)
|
23 (48.9)
|
0
|
0.001
|
|
30-Day mortality, n (%)
|
3 (6.38)
|
0
|
0.035
|
|
Hospital mortality, n (%)
|
22 (46.8)
|
0
|
0.001
|
- CABG coronary artery bypass graft, VAD ventricular assist device, BMI body mass index, CKD chronic kidney disease, CPB cardiopulmonary bypass, APACHE II acute physiology and chronic health evaluation II, SOFA sequential organ failure assessment, MV mechanical ventilation, CRRT continuous renal replacement therapy, PMX-DHP polymyxin B-immobilized fiber column direct hemoperfusion, ECMO extracorporeal membrane oxygenation, DIC disseminated intravascular coagulation.
